South Korea's Daewoong Pharmaceutical Partners with Promedius to Promote AI Osteoporosis Screening Solution Using Chest X-rays
Daewoong Pharmaceutical announced on August 27 that it has signed a sales, distribution, and joint promotion agreement with Promedius, a medical imaging AI company, to promote Osteo Signal, an AI-based osteoporosis risk screening solution using chest X-rays, in South Korea. This partnership also marks Daewoong Pharmaceutical's expansion from its existing osteoporosis treatment business into the AI-assisted diagnostics field. Under the agreement, Daewoong Pharmaceutical will leverage its business network covering medical institutions across South Korea, along with its sales and marketing capabilities, to bring the solution into more clinical settings. Promedius will provide medical imaging AI technical support to assist in its deployment in real-world medical environments.
2026-08-27
